Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Virax Biolabs (VRAX)

Virax Biolabs Group Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VRAX
DateTimeSourceHeadlineSymbolCompany
11/06/202421:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
25/04/202413:00PR Newswire (US)Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
16/04/202412:30PR Newswire (US)Virax Biolabs to Participate at ESCMID Global 2024NASDAQ:VRAXVirax Biolabs Group Ltd
15/03/202420:30PR Newswire (US)Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202422:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
22/01/202422:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VRAXVirax Biolabs Group Ltd
12/01/202412:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202312:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
21/12/202312:30PR Newswire (US)Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID PatientsNASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:12Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
20/12/202321:03Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202312:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202312:30PR Newswire (US)Virax Biolabs' CEO James Foster Issues Letter to ShareholdersNASDAQ:VRAXVirax Biolabs Group Ltd
18/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202312:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
14/12/202312:30PR Newswire (US)Virax Biolabs Group Limited Announces 1-for-10 Share ConsolidationNASDAQ:VRAXVirax Biolabs Group Ltd
08/12/202311:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
05/12/202321:06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:VRAXVirax Biolabs Group Ltd
08/11/202321:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
31/10/202320:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
17/10/202321:05Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VRAXVirax Biolabs Group Ltd
12/10/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
04/10/202312:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202312:49Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
12/09/202312:30PR Newswire (US)Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts WebinarNASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202312:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
01/09/202312:30PR Newswire (US)Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth MomentumNASDAQ:VRAXVirax Biolabs Group Ltd
03/08/202313:39Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:VRAXVirax Biolabs Group Ltd
 Showing the most relevant articles for your search:NASDAQ:VRAX